Unique ID issued by UMIN | UMIN000029357 |
---|---|
Receipt number | R000033552 |
Scientific Title | Safety evaluation of excessive intake of food containing HYA for healthy adults. |
Date of disclosure of the study information | 2017/09/29 |
Last modified on | 2017/12/25 11:32:20 |
Safety evaluation of excessive intake of food containing HYA for healthy adults.
Safety evaluation of excessive intake of food containing HYA
Safety evaluation of excessive intake of food containing HYA for healthy adults.
Safety evaluation of excessive intake of food containing HYA
Japan |
Healthy adult
Adult |
Others
NO
To evaluate the safety of excessive intake of food containing HYA, 5-fold quantity of recommended daily intake, for 4 weeks.
Safety
Hematologic test
Blood biochemistry test
Urine test
Blood pressure/pulsation
Weight/body mass index
Medical Interview
Adverse event
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Prevention
Food |
Consumption of food containing HYA for 5-fold Quantity of recommended daily intake, for 4 weeks.
20 | years-old | <= |
69 | years-old | >= |
Male and Female
(1) Males and females from 20 to 69 years of age
(2) Subjects falling under any of the following
A. fasting blood glucose levels are less than 110 mg/dL or 2-hour glucose levels in 75 g OGTT are less than 140 mg/dL (about 10 subjects)
B. fasting blood glucose levels are ranged 110 to 125 mg/dL or 2-hour glucose levels in 75 g OGTT are ranged 140 to 199 mg/dL (about 10 subjects)
(1) Subjects who routinely use health food containing large amount of unsaturated fatty acids or health food for diet
(2) Subjects who constantly use oral medication and/or functional foods which may affecting serum lipid levels, lipid metabolism and/or glycometabolism
(3) Subjects who have under treatment or a history of serious disease(e.g., diabetes, liver disease, kidney disease, or heart disease)
(4) Subjects having possibilities for emerging allergy related to the test food
(5) Subjects having a disease requiring treatment or a history of serious diseases for which medication was required
(6) Subjects who are judged as unsuitable for the current study based on the results of clinical and physical preliminary examination
(7) Subjects who have participated in other clinical studies within the last one month prior to the current study or are planned to participate in other studies after obtaining informed consent for the current study
(8) Subjects who intend to become pregnant or lactating
(9) Subjects who are judged as unsuitable for the current study based on the results of lifestyle questionnaire
(10) Subjects judged as unsuitable for the current study by the investigator
20
1st name | |
Middle name | |
Last name | Yasunori Yonejima |
NITTO PHARMACEUTICAL INDUSTRIES Co., Ltd.
Research and Development Division
35-3, Minamibiraki., Kamiueno-cho, Muko-shi Kyoto
075-921-5344
y.yonejima@nitto-ph.com
1st name | |
Middle name | |
Last name | Shinsuke Tsuji |
TTC Co., Ltd.
Clinical Research Planning Department
Seibu Shinkin Bank Ebisu Bldg.,1-20-2, Ebisunishi, Shibuya-ku, Tokyo
03-5459-5329
s.tsuji@ttc-tokyo.co.jp
TTC Co., Ltd
NITTO PHARMACEUTICAL INDUSTRIES Co., Ltd.
Profit organization
NO
2017 | Year | 09 | Month | 29 | Day |
Unpublished
Completed
2017 | Year | 09 | Month | 28 | Day |
2017 | Year | 10 | Month | 01 | Day |
2017 | Year | 09 | Month | 29 | Day |
2017 | Year | 12 | Month | 25 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033552